OncologyEducation presents MedOncNow
In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.
21 episodes
Comments
0Be the first to comment
Sign up now and become a member of the OncologyEducation presents MedOncNow community!